ADMA · Adma Biologics, Inc. · Webcasts, Transcripts & Audio
$13.36
+0.02 (+0.15%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$2.96B
Shares
221.85M
Volume · Nov 20
284.76K
Avg daily vol (3M)
3.2M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Adma Biologics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Adma Biologics, Inc. (ADMA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Adma Biologics, Inc. (ADMA) Q3 2026 Earnings Call
Revenue
$141.10M
▲ 5.1% YoY Diluted EPS
$0.22
▲ 46.7% YoY Gross margin
70.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
Adma Biologics, Inc. (ADMA) Q2 2026 Earnings Call Transcript
Confident tone
SG001 pipeline development
Financial performance and cash generation
Standard IG / Bivigam competitive pressures
Revenue
$124.39M
▲ 2% YoY Diluted EPS
$0.16
▲ 14.3% YoY Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-06-02
Adma Biologics, Inc. (ADMA) June 2, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Adma Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
Positive tone
Ascentive demand growth
Pediatric label expansion
Vivigam competitive pressure
Revenue
$114.49M
▼ 0.3% YoY Diluted EPS
$0.19
▲ 72.7% YoY Gross margin
70.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Adma Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
Confident tone
Financial results and profitability
Ascentive product growth and demand
Yield-enhanced manufacturing
Revenue
$139.16M*
▲ 18.4% YoY Gross margin
63.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Adma Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript
Confident tone
Financial performance and profitability
Capital deployment and guidance
Plasma supply and inventory build
Revenue
$134.22M
▲ 12% YoY Diluted EPS
$0.15
▲ 0% YoY Gross margin
56.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Adma Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript
Confident tone
Revenue Growth & Financial Performance
Yield Enhancement / Manufacturing Efficiency
Facility Expansion & Capacity Planning
Revenue
$121.98M
▲ 13.8% YoY Diluted EPS
$0.14
▲ 7.7% YoY Gross margin
55.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Adma Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
Confident tone
Revenue Growth and Guidance
ASCENIV Franchise and Durability
Yield Enhancement Production Process
Revenue
$114.80M
▲ 40.2% YoY Diluted EPS
$0.11
▲ 37.5% YoY Gross margin
53.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Adma Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript
Confident tone
Revenue and earnings momentum
ASCENIV product growth and market penetration
Enhanced yield production process (regulatory)
Revenue
$117.55M*
▲ 59.1% YoY Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Adma Biologics, Inc. (ADMA) Q3 2024 Earnings Call Transcript
Confident tone
ASCENIV Commercial Momentum
Yield Enhancement Initiative
Revenue and Earnings Growth
Revenue
$119.84M
▲ 78.1% YoY Diluted EPS
$0.15
▲ 1400% YoY Gross margin
49.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Adma Biologics, Inc. (ADMA) Q2 2024 Earnings Call Transcript
Confident tone
ASCENIV demand and penetration
Raised financial guidance
Revenue growth and milestone
Revenue
$107.19M
▲ 78.3% YoY Diluted EPS
$0.13
Gross margin
53.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Adma Biologics, Inc. (ADMA) Q1 2024 Earnings Call Transcript
Confident tone
Asceniv commercial momentum
Post-2025 outlook uncertainty
Revenue growth and outperformance
Revenue
$81.88M
▲ 43.9% YoY Diluted EPS
$0.08
Gross margin
47.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Adma Biologics, Inc. (ADMA) Q4 2023 Earnings Call Transcript
Confident tone
Forward Guidance / Outlook
ASCENIV Product Performance
Revenue and Earnings Growth
Revenue
$73.90M*
▲ 47.9% YoY Gross margin
42.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Adma Biologics, Inc. (ADMA) Q3 2023 Earnings Call Transcript
Revenue
$67.28M
▲ 63.7% YoY Diluted EPS
$0.01
Gross margin
36.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Adma Biologics, Inc. (ADMA) Q2 2023 Earnings Call Transcript
Revenue
$60.12M
▲ 77.3% YoY Diluted EPS
$-0.03
Gross margin
27.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Adma Biologics, Inc. (ADMA) Q1 2023 Earnings Call Transcript
Revenue
$56.91M
▲ 95.6% YoY Diluted EPS
$-0.03
Gross margin
29.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Adma Biologics, Inc. (ADMA) Q4 2022 Earnings Call Transcript
Revenue
$49.98M*
▲ 89.4% YoY Gross margin
28.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Adma Biologics, Inc. (ADMA) Q3 2022 Earnings Call Transcript
Revenue
$41.09M
▲ 98.7% YoY Diluted EPS
$-0.08
Gross margin
23.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Adma Biologics, Inc. (ADMA) Q2 2022 Earnings Call Transcript
Revenue
$33.91M
▲ 90.2% YoY Diluted EPS
$-0.07
Gross margin
22.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Adma Biologics, Inc. (ADMA) Q1 2022 Earnings Call Transcript
Revenue
$29.10M
▲ 81.3% YoY Diluted EPS
$-0.13
Gross margin
12.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-19
Adma Biologics, Inc. (ADMA) Q4 2021 Earnings Call Transcript
Revenue
$26.38M*
▲ 89% YoY Gross margin
13.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Adma Biologics, Inc. (ADMA) Q3 2021 Earnings Call Transcript
Revenue
$20.68M
▲ 101.2% YoY Diluted EPS
$-0.13
Gross margin
1.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Adma Biologics, Inc. (ADMA) Q2 2021 Earnings Call Transcript
Revenue
$17.83M
▲ 129% YoY Diluted EPS
$-0.15
Gross margin
-5.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Adma Biologics, Inc. (ADMA) Q1 2021 Earnings Call Transcript
Revenue
$16.05M
▲ 57.3% YoY Diluted EPS
$-0.16
Gross margin
-10.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Adma Biologics, Inc. (ADMA) Q4 2020 Earnings Call Transcript
Revenue
$13.96M*
▲ 15.9% YoY Gross margin
-36.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Adma Biologics, Inc. (ADMA) Q3 2020 Earnings Call Transcript
Revenue
$10.28M
▲ 42.3% YoY Diluted EPS
$-0.19
Gross margin
-15.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Adma Biologics, Inc. (ADMA) Q2 2020 Earnings Call Transcript
Revenue
$7.79M
▲ 18.7% YoY Diluted EPS
$-0.23
Gross margin
-73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Adma Biologics, Inc. (ADMA) Q1 2020 Earnings Call Transcript
Revenue
$10.20M
▲ 189.1% YoY Gross margin
-65.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-13
Adma Biologics, Inc. (ADMA) Q4 2019 Earnings Call
Revenue
$12.04M*
▲ 196.7% YoY Gross margin
2.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1368514
CUSIP
000899104
13F (30d)
333 filings
305 filers
Visit website
Investor relations